DiNAQOR CSO Thomas Voit Featured in Nature Research
DiNAQOR CSO Thomas Voit discusses trends in cardiovascular gene therapy and the company’s partnership with BioMarin with Nature Research.
Uncategorized
DiNAQOR AG Appoints Eduard Ayuso as Chief Technology Officer
DiNAQOR announced that Eduard Ayuso, D.V.M., Ph.D. has been appointed as Chief Technology Officer.
DiNAQOR AG Expands Global R&D Operations with New Zurich Facility
DiNAQOR announced the expansion of its global research and development operations with a new facility in the Bio-Technopark Schlieren-Zürich.
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
BioMarin Pharmaceutical has entered into a preclinical collaboration and license agreement with DiNAQOR to develop novel gene therapies to treat rare genetic cardiomyopathies.
DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure
DiNAQOR today announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies
Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies
Strategic collaboration to focus on DiNAQOR’s adeno-associated virus gene therapy production system Companies to partner on gene therapy process and analytical development for preclinical, clinical and commercial production of DiNA-001, DiNAQOR’s lead preclinical program Process development and manufacturing to be located at Lonza, Houston (US), Center of Excellence for cell-and-gene-therapy manufacturing Quote from Alberto Santagostino, … Read more